Breaking Down SG&A Expenses: United Therapeutics Corporation vs PTC Therapeutics, Inc.

Comparing SG&A Strategies: United vs. PTC Therapeutics

__timestampPTC Therapeutics, Inc.United Therapeutics Corporation
Wednesday, January 1, 201444820000381287000
Thursday, January 1, 201582080000452612000
Friday, January 1, 201697130000316800000
Sunday, January 1, 2017121271000330100000
Monday, January 1, 2018153548000265800000
Tuesday, January 1, 2019202541000336200000
Wednesday, January 1, 2020245164000423900000
Friday, January 1, 2021285773000467000000
Saturday, January 1, 2022325998000487000000
Sunday, January 1, 2023332540000477100000
Loading chart...

Unveiling the hidden dimensions of data

SG&A Expenses: A Tale of Two Therapeutics

In the competitive landscape of biotechnology, understanding the financial strategies of leading companies is crucial. Over the past decade, United Therapeutics Corporation and PTC Therapeutics, Inc. have demonstrated distinct approaches in managing their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, United Therapeutics consistently allocated a higher percentage of their revenue to SG&A, peaking at approximately 48% in 2022. In contrast, PTC Therapeutics showed a steady increase, with their SG&A expenses growing by over 640% during the same period. This divergence highlights United Therapeutics' focus on maintaining robust administrative operations, while PTC Therapeutics appears to be ramping up its market presence. As the biotech sector evolves, these financial strategies will play a pivotal role in shaping the future trajectories of these companies.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025